Results 21 to 30 of about 2,911,119 (244)

Combating Acquired TRK Inhibitor Resistance [PDF]

Cancer Discovery, 2019
Abstract Preliminary findings from a phase I study of LOXO-195 show that the investigational agent appears effective in patients with NTRK fusion–positive solid tumors that have become resistant to first-generation TRK inhibitors.
openaire   +2 more sources

The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain [PDF]

Journal of Medicinal Chemistry, 2016
The neurotrophin family of growth factors, comprised of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4), is implicated in the physiology of chronic pain.
Angus Nedderman, Colin Robinson, David Brown, Gareth Waldron, Inaki Morao, James Bilsland, Karl R Gibson, Kimberly Skinner, Kiyoyuki Omoto, Mark Andrews, Paul Stupple, Peter J. Bungay, Russell Jones, Sarah E. Skerratt, Sharan K. Bagal, Susan Cole, Swarbrick M. E., Thomas Ryckmans   +17 more
core   +4 more sources

Case report: NTRK1-rearranged cervical sarcoma with fibrosarcoma like morphology presenting in a 13-year-old managed with a neo-adjuvant TRK-inhibitor and surgical excision [PDF]

Gynecol Oncol Rep, 2021
E. Goulding, P. Morreau, M. De Silva, M. Watson, C. van Vliet, B. Leung, L. Eva   +6 more
semanticscholar   +2 more sources

Sustained response to larotrectinib in a pediatric patient with recurrent STRN3::NTRK2 fusion-positive pilocytic astrocytoma [PDF]

CNS Oncology
A 7-year-old female with recurrent midline pilocytic astrocytoma harboring a rare STRN3::NTRK2 fusion achieved sustained near-complete radiographic and clinical response to larotrectinib, a selective TRK inhibitor.
Kishore Balasubramanian, Kar-Ming Fung, Rene Y. McNall-Knapp, Karl Balsara   +3 more
doaj   +2 more sources

Characterization of On-Target Adverse Events Caused by TRK Inhibitor Therapy. [PDF]

Ann Oncol, 2020
Dazhi Liu, J. Flory, J. Flory, A. Lin, A. Lin, M. Offin, M. Offin, C. Falcon, Y. Murciano-Goroff, Ezra Y. Rosen, Robin Guo, E. Basu, Bob T. Li, Bob T. Li, James J. Harding, James J. Harding, Gopa Iyer, Gopa Iyer, K. Jhaveri, K. Jhaveri, M. Gounder, M. Gounder, N. Shukla, S. S. Roberts, S. S. Roberts, Julia L. Glade-Bender, L. Kaplanis, A. Schram, A. Schram, David M. Hyman, David M. Hyman, A. Drilon, A. Drilon   +32 more
semanticscholar   +2 more sources

Comprehensive characterization and targeted treatment of a pediatric epithelioid glioblastoma with a rare TRIM24-NTRK2 fusion [PDF]

npj Precision Oncology
High-grade gliomas are one of the most lethal cancers and the leading cause of cancer-related mortality in children. Standard treatment typically involves resection, chemotherapy and radiation, yet offer limited improvement in survival rates.
Simon Keane, Ida Sjöberg, Lily Deland, Angelica Lindlöf, Thomas Olsson Bontell, Teresia Kling, Malin Blomstrand, Henrik Fagman, Jonas A. Nilsson, Daniel Nilsson, Magnus Sabel, Helena Carén, Frida Abel   +12 more
doaj   +2 more sources

Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy [PDF]

J Mol Diagn, 2019
S. Hsiao, A. Zehir, A. Sireci, D. Aisner
semanticscholar   +2 more sources

Case Report: Novel findings of larotrectinib in children with NTRK-rearranged spindle cell tumor [PDF]

Frontiers in Oncology
Neurotrophic tropomyosin receptor kinase (NTRK)-rearranged spindle cell tumors are often resistant to chemotherapy and radiotherapy. Fortunately, they are sensitive to targeted therapy of tropomyosin receptor kinase (TRK) inhibitors. However, the data on
Linnan Wu, Linnan Wu, Weiji Xie, Weiji Xie, Juan Wang, Juan Wang, Suying Lu, Suying Lu, Yizhuo Zhang, Yizhuo Zhang, Junting Huang, Junting Huang   +11 more
doaj   +2 more sources

TRK Inhibitor [PDF]

Definitions, 2020
openaire   +2 more sources

TRK Inhibitor LOXO-195 [PDF]

Definitions, 2020
openaire   +2 more sources